IMM2510, an Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein for Advanced IO-treated SQ-NSCLC: A Phase I Study

Milestone Payment of $5 Million Received for IMM2510 and IMM27M Collaboration between ImmuneOnco and Instil Bio

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today is pleased to announce preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China.

SHANGHAI and DALLAS,TX, July 2, 2025 (GLOBE NEWSWIRE)– ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”) and Instil Bio, Inc. (Nasdaq: TIL, "Instil") , today announced the clearance of an Investigational New Drug (IND) application for IMM2510/AXN-2510 by the U.S. Food and Drug Administration.

IMM0306 has demonstrated a strong efficacy signal in the preliminary data for SLE, with efficient and sustained B-cell depletion and immune reconstitution. It has shown rapid and dose-dependent improv